Get the Stockscreener App
8.60
1.30%
0.11
Aardvark Therapeutics Inc stock is traded at $8.60, with a volume of 139.79K.
It is up +1.30% in the last 24 hours and down -31.47% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$8.49
Open:
$8.25
24h Volume:
139.79K
Relative Volume:
2.06
Market Cap:
$186.59M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+3.61%
1M Performance:
-31.47%
6M Performance:
-24.43%
1Y Performance:
+0.00%
1-Day Range:
$8.25
$8.99
1-Week Range:
$8.03
$9.09
52-Week Range:
$4.88
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
8.60 | 184.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
Aardvark Therapeutics Inc Stock (AARD) Latest News
Developing predictive dashboards with Aardvark Therapeutics Inc. dataEarnings Miss & Breakout Confirmation Alerts - Newser
What MACD signals say about Aardvark Therapeutics Inc.July 2025 Breakouts & Fast Gain Swing Alerts - Newser
Candlestick signals on Aardvark Therapeutics Inc. stock today2025 Biggest Moves & Fast Moving Market Watchlists - Newser
Can volume confirm reversal in Aardvark Therapeutics Inc.2025 Historical Comparison & AI Driven Stock Movement Reports - Newser
Aardvark Therapeutics Inc. stock chart pattern explainedOil Prices & Free Technical Pattern Based Buy Signals - Newser
Real time breakdown of Aardvark Therapeutics Inc. stock performanceJuly 2025 Opening Moves & Verified Chart Pattern Signals - Newser
Custom watchlist performance reports with Aardvark Therapeutics Inc.Sell Signal & Precise Swing Trade Entry Alerts - Newser
Is Aardvark Therapeutics Inc. a candidate for recovery play2025 Dividend Review & Free High Accuracy Swing Entry Alerts - Newser
Is Aardvark Therapeutics Inc. stock a smart retirement pickEarnings Recap Summary & Safe Capital Growth Plans - خودرو بانک
Will Aardvark Therapeutics Inc. stock recover after earningsJuly 2025 Technicals & Community Consensus Stock Picks - خودرو بانک
Can Aardvark Therapeutics Inc. recover in the next quarterJuly 2025 Institutional & High Accuracy Buy Signal Tips - Newser
What high frequency data says about Aardvark Therapeutics Inc.Options Play & Low Volatility Stock Recommendations - Newser
Will Aardvark Therapeutics Inc. stock go up soonJuly 2025 Rallies & Short-Term High Return Strategies - Newser
Statistical indicators supporting Aardvark Therapeutics Inc.’s strengthOil Prices & Consistent Growth Equity Picks - Newser
Aardvark Therapeutics Inc. stock daily chart insightsJuly 2025 Patterns & Free Community Consensus Stock Picks - Newser
How to build a custom watchlist for Aardvark Therapeutics Inc.July 2025 Levels & Real-Time Stock Movement Alerts - Newser
Is Aardvark Therapeutics Inc. stock showing strong momentum2025 Sector Review & Expert-Curated Trade Recommendations - خودرو بانک
What’s next for Aardvark Therapeutics Inc. stock priceJuly 2025 Chart Watch & Low Drawdown Momentum Trade Ideas - Newser
Aardvark Therapeutics reports inducement grants under Nasdaq listing rule - TipRanks
Will Aardvark Therapeutics Inc. bounce back from current supportJuly 2025 Intraday Action & Daily Stock Trend Reports - Newser
How to forecast Aardvark Therapeutics Inc. trends using time seriesTrade Risk Assessment & Community Verified Trade Signals - Newser
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Can machine learning forecast Aardvark Therapeutics Inc. recoveryMarket Performance Recap & Stock Portfolio Risk Management - Newser
Tick level data insight on Aardvark Therapeutics Inc. volatilityPortfolio Gains Report & Risk Controlled Daily Plans - Newser
Tools to assess Aardvark Therapeutics Inc.’s risk profileJuly 2025 Sector Moves & Breakout Confirmation Alerts - Newser
Is Aardvark Therapeutics Inc. stock overvalued or fairly pricedJuly 2025 Summary & Verified Entry Point Detection - خودرو بانک
Aardvark Therapeutics (AARD): Pioneering Gut-Brain Signaling to Disrupt Obesity and Metabolic Disease Therapies - AInvest
Aardvark Therapeutics’ Strategic Position in Metabolic Disease Innovation - AInvest
Should you buy the dip on Aardvark Therapeutics Inc.July 2025 Rallies & Expert-Curated Trade Recommendations - خودرو بانک
Combining machine learning predictions for Aardvark Therapeutics Inc.Gold Moves & Verified Momentum Stock Alerts - Newser
Aardvark Therapeutics Updates Corporate Presentation on Strategy - TipRanks
Can Aardvark Therapeutics Inc. continue delivering strong returns2025 Dividend Review & Trade Opportunity Analysis Reports - خودرو بانک
Does Aardvark Therapeutics Inc. offer margin of safetyQuarterly Profit Report & Smart Swing Trading Techniques - خودرو بانک
Should I average down on Aardvark Therapeutics Inc. stock2025 Market Trends & Fast Moving Stock Trade Plans - خودرو بانک
Is Aardvark Therapeutics Inc. stock a good dividend stockJuly 2025 Update & Growth Focused Entry Reports - خودرو بانک
Will Aardvark Therapeutics Inc. outperform its industry peersOil Prices & Daily Stock Trend Watchlist - خودرو بانک
Analyzing Aardvark Therapeutics Inc. with risk reward ratio chartsMarket Sentiment Review & Safe Capital Allocation Plans - Newser
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):